(19)
(11) EP 2 885 304 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.12.2016 Bulletin 2016/49

(45) Mention of the grant of the patent:
21.09.2016 Bulletin 2016/38

(21) Application number: 13762619.8

(22) Date of filing: 16.08.2013
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61P 29/00(2006.01)
 A61K 31/4162(2006.01)
(86) International application number:
PCT/US2013/055275
(87) International publication number:
WO 2014/028805 (20.02.2014 Gazette 2014/08)

(54)

PYRROLOPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS

PYRROLOPYRAZOLE ALS N-TYP-CALCIUM-KANAL-BLOCKER

PYRROLOPYRAZOLES COMME BLOQUEURS DU CANAL CALCIQUE DE TYPE N

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.08.2012 US 201261683780 P

(43) Date of publication of application:
24.06.2015 Bulletin 2015/26

(73) Proprietor: Janssen Pharmaceutica NV
2340 Beerse (BE)

(72) Inventors:
  • WINTERS, Michael, P.
    Morgantown, PA 19543 (US)
  • SUI, Zhihua
    Piscataway, NJ 08854 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A1-2004/094429
WO-A2-98/22442
 WO-A1-2005/073197
   
  • NALIN L. SUBASINGHE ET AL: "A novel series of pyrazolylpiperidine N-type calcium channel blockers", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 22, no. 12, 2 May 2012 (2012-05-02), pages 4080-4083, XP028509340, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2012.04.075 [retrieved on 2012-05-02]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).